港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

恒瑞医药

82.850

-1.450-1.72%

成交量：372.79万

成交额：3.08亿

市值：5,498.75亿

市盈率：76.00

高：85.100

开：81.700

低：80.850

收：84.300

52周最高：95.200

52周最低：52.500

股本：66.37亿

香港流通股本：2.58亿

量比：1.84

换手率：1.44%

股息：- -

股息率：- -

每股收益(LYR):1.090

净资产收益率：14.41%

总资产收益率：8.45%

市净率：8.63

市盈率(LYR):76.00

市销率: 16.73

数据加载中...

总览公司新闻公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻

又一个“全球首款”减肥药来了，但胖子快要不够用了

恒瑞重返第一，百利天恒首登，六成公司“新晋”，谁在定义药企竞争力？2025年竞争力20强揭榜

国产PDE4抑制剂破局上市，银屑病治疗迎来“中国方案”

CPHI制药在线

2025年医药研发行业发展现状及未来趋势展望分析

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/01276"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":82.85,"timestamp":1760342908003,"preClose":84.3,"halted":0,"volume":3727916,"delay":0,"floatShares":258000000,"shares":6637000000,"eps":1.090186254220673,"marketStatus":"未开盘","change":-1.45,"latestTime":"10-13 16:08:28","open":81.7,"high":85.1,"low":80.85,"amount":307972938,"amplitude":0.050415,"askPrice":82.85,"askSize":6600,"bidPrice":82.8,"bidSize":600,"shortable":3,"etf":0,"ttmEps":1.2651720498856331,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1760405400000},"marketStatusCode":0,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":84.3,"openAndCloseTimeList":[[1760319000000,1760328000000],[1760331600000,1760342400000]],"volumeRatio":1.8417769277965432,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":66.98,"timestamp":1760338800000,"preClose":68.2,"halted":0,"volume":53228700,"delay":0,"premium":"+13.46"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":258000000,"roa":"8.45%","roe":"14.41%","lyrEps":1.090186,"volumeRatio":1.8417769277965432,"shares":6637000000,"dividePrice":0,"high":85.1,"amplitude":0.050415,"preClose":84.3,"low":80.85,"week52Low":52.5,"pbRate":"8.63","psRate":"16.73","week52High":95.2,"institutionHeld":0,"latestPrice":82.85,"committee":-0.833333,"eps":1.090186254220673,"divideRate":0,"volume":3727916,"delay":0,"ttmEps":1.2651720498856331,"open":81.7,"prevYearClose":44.05,"prevWeekClose":84.3,"prevMonthClose":88.8,"prevQuarterClose":88.8,"fiveDayClose":93.9,"twentyDayClose":83.1,"sixtyDayClose":71.7,"earningDate":1761580800000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[{"date":"2025-10-28","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761615000000,"name":null,"time":"","dateTimestamp":1761580800000,"actualEps":null},{"date":"2025-08-21","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755739800000,"name":null,"time":"","dateTimestamp":1755705600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1759161600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2025-10-10","current":65.485165,"percent":0.683673,"low":50.027905,"twenty":52.193561,"median":59.039802,"eighty":62.657943,"high":65.582363,"avg":57.860175,"sd":5.048392,"marketCap":496019912951.91},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53},{"date":"2025-05-30","current":53.015805,"twenty":51.822085,"median":52.540895,"eighty":52.926837,"marketCap":395731540422.24},{"date":"2025-06-06","current":52.120101,"twenty":52.130014,"median":52.555929,"eighty":53.075252,"marketCap":390038198012.59},{"date":"2025-06-13","current":52.209491,"twenty":52.177631,"median":52.691227,"eighty":53.357137,"marketCap":390861633032.23},{"date":"2025-06-20","current":50.172412,"twenty":51.591196,"median":52.469796,"eighty":53.075252,"marketCap":374874997562.85},{"date":"2025-06-27","current":50.314776,"twenty":50.363569,"median":52.169666,"eighty":53.013533,"marketCap":376991477472.78},{"date":"2025-07-04","current":51.666141,"twenty":50.343584,"median":52.120101,"eighty":53.004446,"marketCap":387134991658.26},{"date":"2025-07-11","current":55.507007,"twenty":50.44351,"median":52.13337,"eighty":53.090114,"marketCap":415495681161.23},{"date":"2025-07-18","current":57.272274,"twenty":50.582121,"median":52.209491,"eighty":54.057606,"marketCap":428373566715.29},{"date":"2025-07-25","current":54.897923,"twenty":50.594414,"median":52.555929,"eighty":55.711415,"marketCap":412107620053.2},{"date":"2025-08-01","current":59.731878,"twenty":50.855059,"median":52.994419,"eighty":55.972407,"marketCap":445624526286.47},{"date":"2025-08-08","current":59.478715,"twenty":51.107295,"median":53.05296,"eighty":56.541585,"marketCap":444845815775.64},{"date":"2025-08-15","current":61.917611,"twenty":51.356483,"median":53.519848,"eighty":59.478715,"marketCap":462392609292.46},{"date":"2025-08-22","current":58.782188,"twenty":51.569512,"median":54.477764,"eighty":60.15932,"marketCap":470428104569.66},{"date":"2025-08-29","current":59.85298,"twenty":51.666141,"median":55.691374,"eighty":59.937003,"marketCap":481284287403.35},{"date":"2025-09-05","current":65.582363,"twenty":51.677932,"median":55.770266,"eighty":60.732448,"marketCap":526832269752.24},{"date":"2025-09-12","current":62.481332,"twenty":51.8337,"median":55.972407,"eighty":61.285609,"marketCap":502824785657.99},{"date":"2025-09-19","current":63.179889,"twenty":52.120101,"median":56.254853,"eighty":61.852995,"marketCap":508085671393.42},{"date":"2025-09-26","current":63.528382,"twenty":52.146639,"median":56.965096,"eighty":62.270337,"marketCap":509562668601.01},{"date":"2025-10-03","current":64.989073,"twenty":52.165061,"median":57.272274,"eighty":62.504861,"marketCap":522523002865.02},{"date":"2025-10-10","current":61.782766,"twenty":52.193561,"median":59.039802,"eighty":62.657943,"marketCap":496019912951.91}],"updateTime":1760393373139},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2575624233","title":"又一个“全球首款”减肥药来了，但胖子快要不够用了","url":"https://stock-news.laohu8.com/highlight/detail?id=2575624233","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575624233?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 20:34","pubTimestamp":1760358862,"startTime":"0","endTime":"0","summary":"全球首款偏向型减肥药目前市面上已经问世的减肥药，比如司美格鲁肽、替尔泊肽基本都是GLP-1受体激动剂，而先为达的核心产品埃诺格鲁肽是一种偏向性GLP-1RA减重药。作为对比，礼来的替尔泊肽最高剂量15mg的第52周减重约15.1%；诺和诺德的司美格鲁肽在治疗68周后，患者平均体重下降14.9%。对此，有投资者打趣，以后减肥药太多，胖子快要不够用了。先为达生物这样还在冲击ipo的减肥药企业，想要从“诸神混战”中脱颖而出，并不容易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013210657a6b727ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013210657a6b727ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","LU0359201885.HKD","LU0359202008.SGD","91078","LU2543165471.USD","LU0359201612.USD","01276","BK1191"],"gpt_icon":0},{"id":"2575336762","title":"恒瑞重返第一，百利天恒首登，六成公司“新晋”，谁在定义药企竞争力？2025年竞争力20强揭榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2575336762","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575336762?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 20:08","pubTimestamp":1760357280,"startTime":"0","endTime":"0","summary":"医药行业正从“增量时代”过渡到“存量竞争”，韧性成为药企新竞争力，涵盖修复力、适应力与再生力。这种能力不仅体现在账面业绩稳定，更在于结构上的自我调整，如产品结构切换、商业模型重新配置及组织管理弹性。2024年，医药行业持续调整，表现不振，但仍有众多优秀公司逆周期增长。2025年中国医药上市公司竞争力20强展示了具备“穿越周期”潜力的药企，它们主动求变，承受压力并快速“修复”。面对行业结构性拐点，药企需从产品创新、商业卓越、动态管理三方面入手，实现韧性发展。2025年榜单新上榜公司增至12家，过半公司变动，凸显行业变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014011436972ba8f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014011436972ba8f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","01276","BK1191","LU0359202008.SGD","91194","LU0359201612.USD","LU2543165471.USD","LU0359201885.HKD"],"gpt_icon":0},{"id":"2575690233","title":"国产PDE4抑制剂破局上市，银屑病治疗迎来“中国方案”","url":"https://stock-news.laohu8.com/highlight/detail?id=2575690233","media":"CPHI制药在线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575690233?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 18:08","pubTimestamp":1760350102,"startTime":"0","endTime":"0","summary":"关注并星标CPHI制药在线2025年10月11日，国家药监局官网显示，和美药业研发的1类新药“莫米司特”正式获批上市，用于治疗斑块状银屑病。这不仅是中国首个自主研发的PDE4抑制剂，也标志着国产创新药在自身免疫疾病领域迈出了关键一步。终于在 2025 年 10 月 11 日，国家药监局官网显示，莫米司特片获批上市，成为首款获批的国产 PDE4 抑制剂。在莫米司特获批之前，国内 PDE4 抑制剂市场已有两款进口药物占据一席之地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013182436a45d796f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013182436a45d796f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","LU1023057109.AUD","BK1191","01276","LU0359201612.USD","LU0359201885.HKD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2575233640","title":"2025年医药研发行业发展现状及未来趋势展望分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2575233640","media":"中研网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575233640?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 17:30","pubTimestamp":1760347853,"startTime":"0","endTime":"0","summary":"2025年医保目录首次纳入“商业健康保险创新药品目录”，部分高价值药物可通过商保报销，提升可及性。如需获取完整版报告及定制化战略规划方案，请查看中研普华产业研究院的《中国医药研发行业“十五五”未来趋势预测报告》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013173100a6b6da88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013173100a6b6da88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","BK1574","09939","LU0359201885.HKD","BK1161","LU0359201612.USD","BK1515","LU1023057109.AUD","LU2543165471.USD","LU0359202008.SGD","BK1191"],"gpt_icon":0}],"pageSize":4,"totalPage":50,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/01276\",params:#limit:6,delay:false,,,undefined,":[]}}